hosp恙ira.docxVIP

Medical Distribution HYPERLINK /GlobalEquityData/Screener.aspx?cid=0C00000BBX \t _blank Hospira, Inc. HYPERLINK /GlobalEquityData/overview/overviewframes.aspx?fileid=4787817fsType=BSrType=Anum=12offset=12 \t _blank 0C00000BBX 1 Business General Hospira, Inc. (Hospira) is a global specialty pharmaceutical（药物） and medication delivery company that develops, manufactures and markets products that help improve the safety, cost and productivity of patient care. Hospiras portfolio（业务） includes generic acute-care and oncology（肿瘤学） injectables, as well as integrated infusion therapy（综合灌输治疗） and medication management systems. Hospiras portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. Industry overview Hospira was incorporated in Delaware on September 16, 2003, as a wholly owned subsidiary of Abbott Laboratories (Abbott). On April 30, 2004, Hospira began operating as an independent company, and on May 3, 2004, Hospiras common stock began trading on the New York Stock Exchange under the symbol HSP. In February 2007, Hospira acquired Mayne Pharma Limited (Mayne Pharma), an Australia-based specialty injectable pharmaceutical company listed on the Australian Stock Exchange, for $2,055.0?million in cash. In December 2009, Hospira announced an agreement to acquire a certain business of Orchid Chemicals? Pharmaceuticals?Ltd. (Orchid Pharma), an Indian pharmaceutical company for approximately $400 million. Competition Hospiras industry is highly competitive. Hospira believes that the most effective competitors in its industry are those focused on product quality and performance, breadth of product offering, and manufacturing efficiency as well as the ability to develop and deliver cost-effective products that help hospitals improve the safety of patient care, reduce medication errors and provide high quality care. Hospira believes that it is one of the leading competitors, in terms of U.